Hans Hammers still remembers the early days at UT Southwestern, when the idea of targeting a single protein inside a cancer cell seemed like science fiction. Now, standing in Dallas where decades of research took root, he’s watching that vision change lives: belzutifan, a drug born from local discovery, has just been approved by the FDA to help prevent kidney cancer from coming back in high-risk patients after surgery. This latest green light expands the use of belzutifan—already a breakthrough for rare inherited cancers—into earlier-stage kidney cancer when combined with pembrolizumab, an immunotherapy that helps the immune system recognize and attack cancer cells. The decision, grounded in robust global evidence, offers new hope for patients with clear cell renal cell carcinoma, the most common form of kidney cancer.
For years, treatment options after tumor removal were limited, leaving many patients anxious about recurrence. But the LITESPARK-022 trial, conducted across 285 sites worldwide and led in part by Hammers at UT Southwestern’s Simmons Comprehensive Cancer Center, showed that adding belzutifan to pembrolizumab slashes the risk of the disease returning by 28% compared to pembrolizumab alone. At a median follow-up of 28.4 months, that difference in disease-free survival is already making waves in oncology circles. The results, presented at the 2026 ASCO Genitourinary Cancer Symposium and published in the Journal of Clinical Oncology, mark a meaningful step forward in adjuvant therapy—treatment given after surgery to reduce the chance of cancer returning.
Belzutifan’s journey began not in a boardroom, but in a lab. In the 1990s, UT Southwestern scientists Steven McKnight and David Russell uncovered HIF-2α, a protein that helps cells survive in low-oxygen environments—and, critically, one that fuels kidney cancer growth. Their discovery of a “druggable” pocket in the protein led to the founding of Peloton Therapeutics, where researchers developed belzutifan into a precision therapy. After Merck acquired Peloton in 2019, the drug gained momentum, earning prior approvals for von Hippel-Lindau disease-related tumors and advanced kidney cancer. Now, with this new indication, it’s reaching patients earlier in their journey. Merck manufactures both belzutifan and pembrolizumab, the latter already a cornerstone in cancer immunotherapy.
While overall survival data remains immature, the 28% reduction in recurrence risk is a powerful signal. For patients who’ve undergone major surgery and face the uncertainty of what comes next, this combination offers a stronger shield. It’s a testament to how foundational science—curiosity-driven research from the 1990s—can, decades later, translate into real-world protection. As clinical use expands, doctors are watching closely, hopeful that this advance is just the beginning of a new era in kidney cancer care.
The story of belzutifan is more than a medical milestone—it’s a reminder that persistence in the lab can yield lifelines for patients. And for the growing number of people facing kidney cancer, that persistence is paying off in longer, healthier lives.